# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as ...
HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $2.5 price target.
Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women...
Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fieldsOver 50...
HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from ...
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.0...
After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100%Study ...